These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. K65R, TAMs and tenofovir. Miller MD AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738 [TBL] [Abstract][Full Text] [Related]
8. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine. Marcelin AG; Flandre P; Furco A; Wirden M; Molina JM; Calvez V; Antivir Ther; 2006; 11(6):693-9. PubMed ID: 17310813 [TBL] [Abstract][Full Text] [Related]
9. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. Miller MD; Margot N; Lu B; Zhong L; Chen SS; Cheng A; Wulfsohn M J Infect Dis; 2004 Mar; 189(5):837-46. PubMed ID: 14976601 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Loutfy MR; Raboud JM; Walmsley SL; Saskin R; Montaner JS; Hogg RS; Thompson CA; Harrigan PR Antivir Ther; 2004 Aug; 9(4):595-602. PubMed ID: 15456091 [TBL] [Abstract][Full Text] [Related]
12. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595 [TBL] [Abstract][Full Text] [Related]
13. Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients. Wirden M; Marcelin AG; Simon A; Kirstetter M; Tubiana R; Valantin MA; Paris L; Bonmarchand M; Conan F; Kalkias L; Katlama C; Calvez V J Med Virol; 2005 Jul; 76(3):297-301. PubMed ID: 15902696 [TBL] [Abstract][Full Text] [Related]
15. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439 [TBL] [Abstract][Full Text] [Related]
16. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir. Trotta MP; Bonfigli S; Ceccherini-Silberstein F; Bellagamba R; D'Arrigo R; Soldani F; Zaccarelli M; Concetta Bellocchi M; Lorenzini P; Marconi P; Boumis E; Forbici F; Comandini UV; Tozzi V; Narciso P; Federico Perno C; Antinori A J Med Virol; 2006 May; 78(5):535-41. PubMed ID: 16555278 [TBL] [Abstract][Full Text] [Related]
17. The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir. Theys K; Vercauteren J; Abecasis AB; Libin P; Deforche K; Vandamme AM; Camacho R Infect Genet Evol; 2009 Jul; 9(4):683-8. PubMed ID: 19038365 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study. Dominguez S; Ghosn J; Peytavin G; Izzedine H; Wirden M; Ktorza N; Miller M; Aubron-Olivier C; Trylesinski A; Calvez V; Deray G; Katlama C J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308 [TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. Chappell BJ; Margot NA; Miller MD AIDS; 2007 Mar; 21(6):761-3. PubMed ID: 17413698 [TBL] [Abstract][Full Text] [Related]
20. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]